Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma
BMS will conduct a regulatory postmarketing surveillance (PMS) to evaluate the safety of elotuzumab in clinical practice in Japan.
Multiple Myeloma
OTHER: No Intervention
Incidence of all adverse events(AE) to elotuzumab in real-world practice in Japan, Up to 72 weeks|Incidence of immune-related (IR) adverse events to elotuzumab in real-world practice in Japan, immune-related (IR) adverse events are defined as: 1) AEs that are related to elotuzumab per investigator and 2) are consistent with an inflammatory process., Up to 72 weeks|Number of patients who achieve a Stringent complete response (sCR) as measured by International Myeloma Working Group (IMWG) criteria, Up to 72 weeks|Number of patients who achieve a Complete response (CR) as measured by International Myeloma Working Group (IMWG) criteria, Up to 72 weeks|Number of patients who achieve a Very good partial response (VGPR) as measured by International Myeloma Working Group (IMWG) criteria, Up to 72 weeks|Number of patients who achieve a Partial response (PR) as measured by International Myeloma Working Group (IMWG) criteria, Up to 72 weeks|Number of patients who achieve a Progressive Disease (PD) as measured by International Myeloma Working Group (IMWG) criteria, Up to 72 weeks|Number of patients who achieve a Relapse from complete response as measured by International Myeloma Working Group (IMWG) criteria, Up to 72 weeks
BMS will conduct a regulatory postmarketing surveillance (PMS) to evaluate the safety of elotuzumab in clinical practice in Japan.